New drug combo targets Hard-to-Treat cancers with RAS mutations
NCT ID NCT07678593
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and effective at shrinking tumors. The trial involves about 222 participants and is conducted in two phases: first to check safety, then to measure tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GFH276 (oral drug) combined with cetuximab or chemotherapy (nab-paclitaxel, gemcitabine, fluorouracil, leucovorin)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced solid tumors or pancreatic cancer that have a RAS mutation.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so the drug may not work as hoped or could cause significant side effects. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Macquarie University / Clinical Trials Unit
North Ryde, New South Wales, 2109, Australia
Contact
Contact
-
Monash Health (Monash Medical Centre)
Clayton, Victoria, 3168, Australia